Sex cord stromal tumors and tumors of the paratestis: new and old entities in a landscape of rare tumors
Purpose of review
The 5th edition of WHO classification incorporates the most relevant new data available in the literature regarding tumors of the male genitourinary tract. In this review, the authors summarize and critically discuss the most relevant new information regarding tumors occurring in the stromal testis and in the paratestis that will be reported in the new edition of WHO classification of tumors of the male genitourinary tract.
Recent findings
Signet-ring stromal tumors (SRST) and myoid gonadal stromal tumors (MGST) are two new entities brought in the 5th WHO classification of testicular tumors. Al...
Source: Current Opinion in Urology - June 29, 2022 Category: Urology & Nephrology Tags: URO PATHOLOGY: Edited by Eva M. Compérat Source Type: research
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines
Curr Oncol. 2022 Jun 1;29(6):4020-4033. doi: 10.3390/curroncol29060321.ABSTRACTFew studies have reported hormonal agent use in the treatment of low-grade serous ovarian carcinomas (LGSOCs), which are chemoresistant. Considering the need for novel effective therapies, we investigated the hormone receptor expression and hormonal inhibition efficacy in LGSOCs. Using immunohistochemistry, we assessed the estrogen receptor (ER) expression status in 33 cases of histologically confirmed serous ovarian tumors, including 10, 11, and 12 cases of LGSOCs, serous borderline tumors (SBTs), and serous cystadenomas (SCAs), respectively. T...
Source: Current Oncology - June 23, 2022 Category: Cancer & Oncology Authors: Kamrunnahar Shanta Kentaro Nakayama Mohammad Mahmud Hossain Sultana Razia Tomoka Ishibashi Masako Ishikawa Hitomi Yamashita Kosuke Kanno Seiya Sato Satoru Nakayama Yoshiro Otsuki Satoru Kyo Source Type: research
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines
Curr Oncol. 2022 Jun 1;29(6):4020-4033. doi: 10.3390/curroncol29060321.ABSTRACTFew studies have reported hormonal agent use in the treatment of low-grade serous ovarian carcinomas (LGSOCs), which are chemoresistant. Considering the need for novel effective therapies, we investigated the hormone receptor expression and hormonal inhibition efficacy in LGSOCs. Using immunohistochemistry, we assessed the estrogen receptor (ER) expression status in 33 cases of histologically confirmed serous ovarian tumors, including 10, 11, and 12 cases of LGSOCs, serous borderline tumors (SBTs), and serous cystadenomas (SCAs), respectively. T...
Source: Current Oncology - June 23, 2022 Category: Cancer & Oncology Authors: Kamrunnahar Shanta Kentaro Nakayama Mohammad Mahmud Hossain Sultana Razia Tomoka Ishibashi Masako Ishikawa Hitomi Yamashita Kosuke Kanno Seiya Sato Satoru Nakayama Yoshiro Otsuki Satoru Kyo Source Type: research
